IN8bio, Inc. (INAB) vs Lantern Pharma Inc. (LTRN)
A side-by-side comparison of IN8bio, Inc. and Lantern Pharma Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INAB
IN8bio, Inc.
$1.43HealthcareDelayed quote: Oct 6, 2026, 10:17 AM EDT
LTRN
Lantern Pharma Inc.
$0.93HealthcareDelayed quote: Oct 6, 2026, 10:24 AM EDT
Total return — INAB vs LTRN
growth of $100 · dividends reinvested · last 5yINAB -99.5% (-65.7%/yr)LTRN -92.7% (-40.8%/yr)LTRN compounded faster over this window
Log scale — wide-divergence pair
INAB LTRN
INAB vs LTRN: by the numbers
- •INAB is the larger company ($14M vs $12M market cap).
Metrics side by side
Valuation
| Metric | INAB | LTRN |
|---|---|---|
| P/B ratio | 0.74 | N/A |
Profitability
| Metric | INAB | LTRN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -101.66% | N/A |
| ROIC | -91.74% | -358.04% |
Growth (annualized)
| Metric | INAB | LTRN |
|---|---|---|
| Total return CAGR (5Y) | -62.88% | -37.05% |
Frequently asked
- How have INAB and LTRN total returns compared?
- Over the past 5 years, INAB delivered -62.88% and LTRN delivered -37.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.